{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:01:31Z","timestamp":1789999291790,"version":"4.0.1"},"reference-count":46,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Research, Ricerca Corrente 2026"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Melanoma disproportionately affects older adults, who account for a growing share of cases as populations age. Its incidence rises with age, and the number of ultra-octogenarians (\u226585 years) is expected to triple by 2050, particularly in high-incidence regions such as Australia, North America and Europe. Moreover, older adults frequently present with substantial comorbidities, making management complex and complicating treatment decisions. Methods: This comprehensive review summarizes evidence concerning the clinicopathological characteristics, treatment patterns, systemic therapy outcomes, and geriatric considerations relevant to patients aged 75 years or older with melanoma. PubMed\/MEDLINE was searched from January 2000 to March 2026. Reference lists of eligible articles and relevant reviews were examined to identify additional studies. Priority was given to studies reporting age-stratified outcomes for patients aged at least 75 years. Because relatively few studies reported outcomes specifically for patients aged \u226575 years, evidence using thresholds of \u226565, \u226570, or \u226580 years was included when directly relevant. Age thresholds are reported for each study and should not be considered interchangeable. Results: Most evidence specific to patients aged \u226575 years derives from retrospective cohorts and registries. Compared with younger patients, elderly patients more often present with melanomas of the head, neck, hands and feet, a higher prevalence of the nodular subtype, greater Breslow thickness, higher mitotic rates and lower tumor-infiltrating lymphocyte density. Diagnosis is frequently delayed due to difficulties with self-examination, visual impairment, benign age-related skin changes and social factors. Despite presenting such a high-risk disease, older patients are less likely than their younger counterparts to receive immunotherapy or BRAF\/MEK-targeted agents. This treatment gap may reflect comorbidities, altered pharmacokinetics, concerns about toxicity, under-representation in pivotal trials, and limited caregiver support. Available real-world data suggest that the efficacy of immune checkpoint inhibitors and targeted therapies is comparable to that in younger adults, although treatment selection, discontinuation, hospitalization, and dose modification differ across studies. Conclusions: Melanoma in older adults has distinct clinical and pathological patterns, but treatment evidence for patients aged \u226575 years remains limited and subjected to selection bias. Tailored, geriatric-informed treatment strategies integrating tumor biology, comorbidity, functional status and patient preferences are needed to optimize outcomes for patients aged 75 years and older.<\/jats:p>","DOI":"10.3390\/cancers18183057","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:50:03Z","timestamp":1789995003000},"page":"3057","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Melanoma in Advanced Age: A Comprehensive Literature Review of Tumor Biology, Systemic Therapies and Geriatric Challenges"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8605-4290","authenticated-orcid":false,"given":"Nerina","family":"Denaro","sequence":"first","affiliation":[{"name":"Oncologia Medica, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Division of Early Drug Development for Innovative Therapies, European Institute of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), 20141 Milan, Italy"},{"name":"Department of Oncology and Hemato-Oncology (DIPO), University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1314-8226","authenticated-orcid":false,"given":"Dimitrios","family":"Stylianakis","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, School of Medicine, University of Crete, 70013 Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[{"name":"Medical Oncology Division, ASST Sette Laghi, 21100 Varese, Italy"},{"name":"Department of Medicine and Technological Innovation (DiMIT), University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Passoni","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Solinas","sequence":"additional","affiliation":[{"name":"Medical Oncology, AOU Cagliari, Policlinico di Monserrato, 09042 Monserrato, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-5410","authenticated-orcid":false,"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[{"name":"Oncologia Medica, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2014). Ageing and Life-Course: Facts About Ageing, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/CMR.0b013e328335a8dd","article-title":"Cutaneous melanoma in the elderly: Epidemiology, prognosis and treatment","volume":"20","author":"Lasithiotakis","year":"2010","journal-title":"Melanoma Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7857","DOI":"10.18632\/aging.204653","article-title":"The effect of age on melanoma incidence and prognosis","volume":"15","author":"Thompson","year":"2023","journal-title":"Aging"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamadermatol.2013.706","article-title":"Distinctive features of melanoma and its management in elderly patients: A population-based study in France","volume":"149","author":"Ciocan","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Buja, A., Rugge, M., Trevisiol, C., Zanovello, A., Brazzale, A.R., Zorzi, M., Vecchiato, A., Del Fiore, P., Tropea, S., and Rastrelli, M. (2024). Cutaneous melanoma in older patients. BMC Geriatr., 24.","DOI":"10.1186\/s12877-024-04806-8"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jgo.2018.01.001","article-title":"Melanoma in the very elderly, management in patients 85 years of age and over","volume":"9","author":"Rees","year":"2018","journal-title":"J. Geriatr. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archderm.138.5.609","article-title":"Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia","volume":"138","author":"Chamberlain","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2340\/00015555-2944","article-title":"Effect of Age on Melanoma Risk, Prognosis and Treatment Response","volume":"98","author":"Ribero","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III\/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-020-00986-z","article-title":"Immunosenescence: A key player in cancer development","volume":"13","author":"Lian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7150\/jca.2.538","article-title":"Malignant melanoma in the elderly: Different regional disease and poorer prognosis","volume":"2","author":"Macdonald","year":"2011","journal-title":"J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41029","DOI":"10.2340\/actadv.v104.41029","article-title":"Management of melanoma in elderly patients over 80 years","volume":"104","author":"Jourdain","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"115153","DOI":"10.1016\/j.ejca.2024.115153","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment\u2014Update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/2159-8290.CD-18-0193","article-title":"Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility","volume":"9","author":"Kaur","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/2159-8290.CD-18-0168","article-title":"Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis","volume":"9","author":"Ecker","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1245\/s10434-013-3464-x","article-title":"Age as a predictor of sentinel node metastasis among patients with localized melanoma: An inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients","volume":"21","author":"Balch","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","first-page":"e34742","article-title":"Malignant Melanoma in Older Adults: Different Patient or Different Disease?","volume":"15","author":"Sasson","year":"2023","journal-title":"Cureus"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1245\/s10434-009-0420-x","article-title":"Age-related lymphatic dysfunction in melanoma patients","volume":"16","author":"Conway","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/lrb.2007.1023","article-title":"Senile changes in human lymph nodes","volume":"6","author":"Pan","year":"2008","journal-title":"Lymphat. Res. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/CMR.0000000000000430","article-title":"Nicotinamide N-methyltransferase: Potential involvement in cutaneous malignant melanoma","volume":"28","author":"Ganzetti","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s13577-022-00793-3","article-title":"Immunohistochemical expression of nicotinamide N-methyltransferase in lymph node metastases from cutaneous malignant melanoma","volume":"36","author":"Sartini","year":"2023","journal-title":"Hum. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5694\/j.1326-5377.1998.tb126830.x","article-title":"Factors involved in presentation of older people with thick melanoma","volume":"169","author":"Hanrahan","year":"1998","journal-title":"Med. J. Aust."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.suronc.2004.09.002","article-title":"Diagnosis of melanoma in the elderly and surgical implications","volume":"13","author":"Testori","year":"2004","journal-title":"Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/cncr.25726","article-title":"Marital status and stage at diagnosis of cutaneous melanoma","volume":"117","author":"McLaughlin","year":"2011","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/jdv.19772","article-title":"Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients","volume":"38","author":"Dixon","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100577","DOI":"10.1016\/j.esmoop.2022.100577","article-title":"The efficacy of immune checkpoint inhibitors in elderly patients: A meta analysis and meta regression","volume":"7","author":"Kim","year":"2022","journal-title":"ESMO Open"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"de Glas, N.A., Bastiaannet, E., van den Bos, F., Mooijaart, S.P., van der Veldt, A.A.M., Suijkerbuijk, K.P.M., Aarts, M.J.B., van den Berkmortel, F.W.P.J., Blank, C.U., and Boers-Sonderen, M.J. (2021). Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 13.","DOI":"10.3390\/cancers13112826"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/bjc.2014.126","article-title":"Ipilimumab retreatment in patients with pretreated advanced melanoma: The expanded access programme in Italy","volume":"110","author":"Pigozzo","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jgo.2019.12.012","article-title":"Italian Melanoma Intergroup (IMI). Anti-PD1 antibodies in patients aged \u226575 years with metastatic melanoma: A retrospective multicentre study","volume":"11","author":"Ridolfi","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jgo.2019.07.005","article-title":"Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience","volume":"11","author":"Archibald","year":"2020","journal-title":"J. Geriatr. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/cncr.34230","article-title":"Frailty and checkpoint inhibitor toxicity in older patients with melanoma","volume":"128","author":"Bruijnen","year":"2022","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00262-024-03750-1","article-title":"Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients \u2265 75 years: Results of a real-world cohort including 456 patients","volume":"73","author":"Gawaz","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes with Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Reichert, C., Baldini, C., Mezghani, S., Maubec, E., Longvert, C., Mortier, L., Quereux, G., Jannic, A., Machet, L., and de Quatrebarbes, J. (2023). Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients. Cancers, 15.","DOI":"10.3390\/cancers15174330"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jgo.2021.04.006","article-title":"Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry","volume":"12","author":"Jochems","year":"2021","journal-title":"J. Geriatr. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"115056","DOI":"10.1016\/j.ejca.2024.115056","article-title":"Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry","volume":"212","author":"Kapiteijn","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"van der Kooij, M.K., Wetzels, M.J.A.L., Aarts, M.J.B., van den Berkmortel, F.W.P.J., Blank, C.U., Boers-Sonderen, M.J., Dierselhuis, M.P., de Groot, J.W.B., Hospers, G.A.P., and Piersma, D. (2020). Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers, 12.","DOI":"10.3390\/cancers12082072"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"van der Ziel, D., Derks, M.G.M., Kapiteijn, E., Bastiaannet, E., Louwman, M., van den Bos, F., Mooijaart, S.P., Portielje, J.E.A., and de Glas, N.A. (2022). Time Trends in Treatment Strategies and Survival of Older versus Younger Patients with Synchronous Metastasised Melanoma-A Population-Based Study in the Netherlands Cancer Registry. Cancers, 14.","DOI":"10.3390\/cancers14194904"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CMR.0000000000000705","article-title":"Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced\/metastatic melanoma patients","volume":"31","author":"Czarnecka","year":"2021","journal-title":"Melanoma Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/CMR.0000000000000837","article-title":"Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: Real-world data analysis of Spanish patients (ELDERLYMEL)","volume":"32","author":"Medina","year":"2022","journal-title":"Melanoma Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10940","DOI":"10.1038\/s41467-025-65972-w","article-title":"Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study","volume":"16","author":"Lallas","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CMR.0000000000000727","article-title":"BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients","volume":"31","author":"Hernberg","year":"2021","journal-title":"Melanoma Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:14:16Z","timestamp":1789996456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/3057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":46,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18183057"],"URL":"https:\/\/doi.org\/10.3390\/cancers18183057","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}